Nuvation Bio NUVB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's cash & equivalents?
- Nuvation Bio (NUVB) reported cash & equivalents of $125.39M in Q1 2026.
- How has Nuvation Bio's cash & equivalents changed year-over-year?
- Nuvation Bio's cash & equivalents increased by 161.4% year-over-year, from $47.98M to $125.39M.
- What is the long-term trend for Nuvation Bio's cash & equivalents?
- Over 5 years (2020 to 2025), Nuvation Bio's cash & equivalents has grown at a 40.7% compound annual growth rate (CAGR), from $29.76M to $164.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.